Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps

Inclusion Criteria: * Signed informed consent form prior to trial participation, demonstrating full understanding of trial objectives, procedures, and potential adverse reactions. * Age between 18 and 75 years (inclusive) at the time of informed consent signing, regardless of gender. * Diagnosis of bilateral chronic rhinosinusitis with nasal polyps (CRSwNP) meeting the diagnostic criteria of the "Chinese Guidelines for the Diagnosis and Treatment of Chronic Rhinosinusitis (2018)" * At least one prior course of systemic corticosteroids (prednisone 0.5-1 mg/kg/day or 15-30 mg/day or equivalent for minimum 5 days) within 2 years before screening, with persistent bilateral CRSwNP; AND/OR contraindication/intolerance to systemic corticosteroids; AND/OR prior nasal polyp surgery performed more than 6 months before screening. * Bilateral Nasal Polyp Score (NPS) ≥5 (maximum score 8) with ≥2 points per nostril, as assessed by nasal endoscopy during screening and randomization. * Nasal Congestion Score (NCS) ≥2 at screening (daily average) and randomization (weekly average). * Persistent symptoms of rhinorrhea and/or hyposmia/anosmia for over 8 weeks prior to screening. * 22-item Sino-Nasal Outcome Test (SNOT-22) score ≥30 at screening and randomization. * Stable dose of intranasal corticosteroids (INCS) for \>4 weeks prior to screening (subjects using non-mometasone furoate nasal spray \[MFNS\] products must agree to switch to Mometasone Furoate Nasal Spray (MFNS) during the study). …